drugset / Trial / NCT01896102

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

NCT01896102 ↗

Phase 2/3 Completed 32 enrolled Genetix Biotherapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

This trial assessed the efficacy and safety of autologous cluster of differentiation 34 (CD34+) hematopoietic stem cells, transduced ex-vivo with Lenti-D lentiviral vector (also called elivaldogene autotemcel or eli-cel), for the treatment of cerebral adrenoleukodystrophy (CALD). A participant's blood stem cells were collected and modified (transduced) using the Lenti-D lentiviral vector encoding human adrenoleukodystrophy protein. After modification (transduction) with the Lenti-D lentiviral vector, the cells were transplanted back into the participant following myeloablative conditioning. Participants in this study will be continuously followed in study LTF-304.

Timeline

Start
2013-08-21
Primary completion
2021-03-26
Completion
2021-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject elivaldogene tavalentivec Unknown 5e+06 cells/kg Intravenous